Tag : Enter

Latest News

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Newsemia
FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and...
Latest News

Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17

Newsemia
Yang, JC; Roman-Urrestarazu, A; Brayne, C; (2019) Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty...
Latest News

AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa

Newsemia
VALENCIA, Calif., MELBOURNE, Australia & AURORA, Colo.–(BUSINESS WIRE)–AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet...
Biology

Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

Newsemia
SOMERSET, N.J. and WALTHAM, Mass. (PRWEB) September 24, 2019 Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics,...
Latest News

Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States

Newsemia
OSAKA, Japan & SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary,...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy